Stock listing
NASDAQ:BCYC Bicycle Therapeutics PLC Stock
Follow Bicycle Therapeutics PLC into a list and get an email when it puts out news.
Share price · NASDAQ:BCYC
$2.90 USD -0.21 (-6.8%)
Close on Nov 20, 2026
- Day range
- $2.85 – $3.00 USDNov 20, 2026
- Volume
- 1.02M sharesNov 20, 2026
- Market cap
- $146.1M USDAt the close on Nov 20, 2026 · price × 50.37M shares outstanding
- 52-week range
- $2.85 – $7.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.64M USDMedian day 379,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BCYC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.90 | -0.21 | -6.8% | $2.99 | $3.00 | $2.85 | 1,023,517 | |
| $3.11 | -0.09 | -2.8% | $3.20 | $3.27 | $3.095 | 567,648 | |
| $3.20 | +0.02 | +0.6% | $3.18 | $3.22 | $3.12 | 445,392 | |
| $3.18 | -0.19 | -5.6% | $3.33 | $3.36 | $3.07 | 676,101 | |
| $3.37 | -0.08 | -2.3% | $3.45 | $3.50 | $3.26 | 604,366 | |
| $3.45 | -0.24 | -6.5% | $3.65 | $3.655 | $3.43 | 630,100 | |
| $3.69 | 0.00 | 0.0% | $3.73 | $3.75 | $3.665 | 171,799 | |
| $3.69 | -0.08 | -2.1% | $3.77 | $3.78 | $3.65 | 234,733 | |
| $3.77 | +0.16 | +4.4% | $3.69 | $3.84 | $3.57 | 590,237 | |
| $3.61 | +0.13 | +3.7% | $3.50 | $3.685 | $3.49 | 235,641 | |
| $3.48 | -0.24 | -6.5% | $3.69 | $3.69 | $3.465 | 499,184 | |
| $3.72 | +0.05 | +1.4% | $3.75 | $3.80 | $3.65 | 215,100 | |
| $3.67 | +0.05 | +1.4% | $3.61 | $3.71 | $3.61 | 81,485 | |
| $3.62 | -0.04 | -1.1% | $3.69 | $3.76 | $3.58 | 348,214 | |
| $3.66 | -0.16 | -4.2% | $3.75 | $3.80 | $3.60 | 347,481 | |
| $3.82 | -0.06 | -1.5% | $3.92 | $4.13 | $3.71 | 598,172 | |
| $3.88 | +0.10 | +2.6% | $3.76 | $3.89 | $3.71 | 436,241 | |
| $3.78 | +0.13 | +3.6% | $3.66 | $3.84 | $3.61 | 486,229 | |
| $3.65 | +0.10 | +2.8% | $3.66 | $3.69 | $3.53 | 525,704 | |
| $3.55 | -0.09 | -2.5% | $3.64 | $3.64 | $3.415 | 346,800 | |
| $3.64 | +0.07 | +2.0% | $3.56 | $3.64 | $3.525 | 276,200 | |
| $3.57 | -0.03 | -0.8% | $3.62 | $3.797 | $3.56 | 406,400 | |
| $3.60 | +0.065 | +1.8% | $3.53 | $3.71 | $3.52 | 488,100 | |
| $3.535 | +0.075 | +2.2% | $3.45 | $3.64 | $3.41 | 692,100 | |
| $3.46 | -0.14 | -3.9% | $3.58 | $3.60 | $3.42 | 565,600 | |
| $3.60 | +0.09 | +2.6% | $3.51 | $3.64 | $3.50 | 411,500 | |
| $3.51 | -0.12 | -3.3% | $3.63 | $3.755 | $3.50 | 438,300 | |
| $3.63 | -0.17 | -4.5% | $3.81 | $3.88 | $3.63 | 457,200 | |
| $3.80 | -0.09 | -2.3% | $3.89 | $3.91 | $3.785 | 233,300 | |
| $3.89 | +0.08 | +2.1% | $3.81 | $3.92 | $3.775 | 300,600 | |
| $3.81 | +0.08 | +2.1% | $3.71 | $3.81 | $3.62 | 337,700 | |
| $3.73 | -0.06 | -1.6% | $3.75 | $3.805 | $3.68 | 472,600 | |
| $3.79 | -0.22 | -5.5% | $4.02 | $4.025 | $3.735 | 620,700 | |
| $4.01 | +0.63 | +18.6% | $3.62 | $4.039 | $3.61 | 1,844,000 | |
| $3.38 | -0.18 | -5.1% | $3.65 | $3.695 | $3.33 | 728,700 | |
| $3.56 | -0.12 | -3.3% | $3.67 | $3.74 | $3.55 | 379,900 | |
| $3.68 | +0.03 | +0.8% | $3.69 | $3.77 | $3.66 | 295,100 | |
| $3.65 | -0.06 | -1.6% | $3.72 | $3.77 | $3.635 | 206,200 | |
| $3.71 | +0.025 | +0.7% | $3.69 | $3.81 | $3.578 | 442,500 | |
| $3.685 | -0.045 | -1.2% | $3.73 | $3.73 | $3.65 | 238,900 | |
| $3.73 | +0.13 | +3.6% | $3.66 | $3.95 | $3.66 | 820,000 | |
| $3.60 | -0.13 | -3.5% | $3.72 | $3.72 | $3.57 | 374,200 | |
| $3.73 | +0.10 | +2.8% | $3.67 | $3.83 | $3.65 | 554,700 | |
| $3.63 | -0.02 | -0.5% | $3.70 | $3.77 | $3.63 | 266,500 | |
| $3.65 | -0.03 | -0.8% | $3.69 | $3.70 | $3.63 | 240,400 | |
| $3.68 | +0.04 | +1.1% | $3.73 | $3.79 | $3.67 | 185,100 | |
| $3.64 | -0.03 | -0.8% | $3.68 | $3.725 | $3.605 | 599,900 | |
| $3.67 | -0.22 | -5.7% | $3.88 | $3.895 | $3.65 | 544,100 | |
| $3.89 | +0.03 | +0.8% | $3.90 | $3.95 | $3.83 | 209,400 | |
| $3.86 | +0.03 | +0.8% | $3.87 | $3.955 | $3.83 | 621,200 | |
| $3.83 | -0.175 | -4.4% | $3.99 | $3.99 | $3.81 | 1,942,100 | |
| $4.005 | -0.175 | -4.2% | $4.17 | $4.17 | $3.985 | 399,600 | |
| $4.18 | -0.12 | -2.8% | $4.28 | $4.28 | $4.17 | 262,900 | |
| $4.30 | +0.06 | +1.4% | $4.20 | $4.305 | $4.145 | 157,500 | |
| $4.24 | -0.06 | -1.4% | $4.32 | $4.36 | $4.20 | 268,100 | |
| $4.30 | +0.20 | +4.9% | $4.10 | $4.39 | $4.10 | 317,600 | |
| $4.10 | -0.03 | -0.7% | $4.12 | $4.272 | $4.075 | 316,700 | |
| $4.13 | -0.07 | -1.7% | $4.21 | $4.32 | $4.10 | 235,600 | |
| $4.20 | -0.13 | -3.0% | $4.32 | $4.44 | $4.19 | 154,700 | |
| $4.33 | -0.025 | -0.6% | $4.36 | $4.45 | $4.28 | 104,900 | |
| $4.355 | -0.035 | -0.8% | $4.41 | $4.41 | $4.28 | 166,100 | |
| $4.39 | +0.06 | +1.4% | $4.38 | $4.48 | $4.35 | 209,895 | |
| $4.33 | -0.04 | -0.9% | $4.33 | $4.39 | $4.27 | 144,091 | |
| $4.37 | +0.13 | +3.1% | $4.29 | $4.51 | $4.252 | 480,700 | |
| $4.24 | +0.10 | +2.4% | $4.11 | $4.27 | $4.035 | 374,100 |
- Ticker
- NASDAQ:BCYC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 29, 2026
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Latest news
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Oct 29, 2026
Closed $3.82 (-1.5%) on Oct 29, 2026
Bicycle Therapeutics PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Oct 29, 2026 · oldest 2026
- Decks
- 4 decks · latest October 2022
Valuation
EV/sales −3.9× against a median of 17.8×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$323.8M USD
- P/E
- Loss
- EV/sales
- −3.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- Not reported
- Operating margin
- −189.4%
- Net margin
- −169.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.59
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.73M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOT | US$145.3M | −US$46.23M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.49 |
| TYK Medicines, Inc. Class H · HKEX:2410 | US$144.9M | US$137.1M | n/a | n/a | n/a | 3.7× | n/a | 0.6× | n/a |
| Sutro Biopharma, Inc. · NASDAQ:STRO | US$142.8M | US$259.6M | n/a | 5.8× | n/a | n/a | −344.2% | n/a | 1.14 |
| VISEN Pharmaceuticals · HKEX:2561 | US$140.7M | US$91.39M | n/a | 29.9× | n/a | 1.4× | n/a | 0.3× | n/a |
| Median of the others | US$146.7M | US$86.03M | 8.4× | 17.8× | 5.2× | 1.7× | −210.7% | 0.1× | 1.41 |
Forecasts
4 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.26 · 8 analysts
- Revenue, year to Dec 2026
- 38.15M · 9 analysts
Team and board
| Director | Role |
|---|---|
| Hervé Hoppenot | Chairperson |
| Jose-Carlos Gutierrez-Ramos | Chairperson |
| Stephen Sands | Chairperson |
| Alessandro Riva | |
| Felix J. Baker | |
| Roger Dansey |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · Before open | −1.6% |
| Q2 2026 | Jul 30, 2026 · Before open | +3.9% |
| Q1 2026 | Apr 30, 2026 · Before open | −0.2% |
| Q4 2025 | Mar 3, 2026 | −1.8% |
| Q3 2025 | Oct 30, 2025 · Before open | +7.1% |
| Q2 2025 | Aug 8, 2025 · Before open | +2.5% |
| Q1 2025 | May 1, 2025 · Before open | +6.1% |
| Q4 2024 | Feb 18, 2025 · Before open | −3.1% |
| Q3 2024 | Oct 31, 2024 · Before open | −2.4% |
| Q2 2024 | Aug 6, 2024 · Before open | +7.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +2.0% |
| Q4 2023 | Feb 20, 2024 · Before open | +0.8% |
| Q3 2023 | Nov 2, 2023 · Before open | −2.9% |
| Q2 2023 | Aug 3, 2023 · Before open | −0.1% |
| Q1 2023 | May 4, 2023 · Before open | −4.3% |
| Q4 2022 | Feb 28, 2023 · Before open | −2.0% |
| Q3 2022 | Nov 3, 2022 · Before open | −0.5% |
| Q2 2022 | Aug 4, 2022 · Before open | +11.1% |
| Q1 2022 | May 5, 2022 · Before open | −5.6% |
| Q4 2021 | Mar 1, 2022 · Before open | −0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ESCMID 2022 | Conference | 18 slides | October 2022 |
| Technical Presentation (April 2022) | Technical | 23 slides | Apr 12, 2022 |
| Corporate Update (October 2021) | Corporate update | 30 slides | Oct 7, 2021 |
| AACR Annual Meeting 2019 | Conference | 11 slides | 2019 |
IPO
Priced at US$14.00 an ADS on May 22, 2019.
- Price
- US$14.00 an ADS
- ADSs offered
- 4,333,333 American depositary shares
- Offering size
- US$60.7 million
- Underwriters' option
- Up to 650,000 more ADSs
- Listing
- BCYC on the Nasdaq Global Select Market
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Piper Jaffray, Canaccord Genuity · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 21, 2018 |
| Filed publicly | Apr 26, 2019 |
| Amended twice | Newest May 15, 2019 |
| Shares registered with an exchange | May 20, 2019 |
| Declared effective by the SEC | May 22, 2019 |
| Final prospectus, with the price | May 23, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 23, 2019 |
| EFFECT · Notice that a registration is effective | May 22, 2019 |
| CERT · Exchange's certificate of listing | May 22, 2019 |
| CORRESP · Letter to the SEC | May 20, 2019 |
| CORRESP · Letter to the SEC | May 20, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | May 20, 2019 |
| CORRESP · Letter to the SEC | May 20, 2019 |
| UPLOAD · Letter from the SEC | May 16, 2019 |
| S-1/A · Registration statement, amended | May 15, 2019 |
| CORRESP · Letter to the SEC | May 13, 2019 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | May 13, 2019 |
| UPLOAD · Letter from the SEC | May 7, 2019 |
| CORRESP · Letter to the SEC | May 1, 2019 |
| CORRESP · Letter to the SEC | Apr 26, 2019 |
| S-1 · Registration statement | Apr 26, 2019 |
| UPLOAD · Letter from the SEC | Apr 4, 2019 |
| DRSLTR · Letter to the SEC with a draft | Mar 22, 2019 |
| DRS/A · Draft registration statement, amended | Mar 22, 2019 |
| UPLOAD · Letter from the SEC | Feb 12, 2019 |
| DRS · Draft registration statement | Dec 21, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed May 23, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.6M | 35.3M | 27.0M | 14.5M | 11.7M | 10.4M | 13.8M | 7.14M | 2.06M |
| Research and development | 240.3M | 173.0M | 156.5M | 81.6M | 44.9M | 33.1M | 25.5M | 20.8M | 11.9M |
| Operating income | -247.1M | -209.9M | -189.9M | -116.7M | -65.6M | -52.0M | -26.3M | -21.7M | -16.2M |
| Depreciation and amortization | 6.42M | 7.17M | 6.55M | 3.69M | 1.41M | 1.28M | 960.0K | 712.0K | 332.0K |
| EBITDA | -240.6M | -202.7M | -183.4M | -113.0M | -64.2M | -50.7M | -25.3M | -21.0M | -15.9M |
| Interest expense | 206.0K | 1.73M | 3.26M | 3.34M | 2.98M | 457.0K | |||
| Income before tax | -218.8M | -173.8M | -179.2M | -114.2M | -68.5M | -51.7M | -30.9M | -22.2M | -16.3M |
| Income tax | 152.0K | -4.76M | 1.46M | -1.52M | -1.66M | -724.0K | -254.0K | -396.0K | -23.0K |
| Net income | -219.0M | -169.0M | -180.7M | -112.7M | -66.8M | -51.0M | -30.6M | -21.8M | -16.3M |
| Earnings per share, basic | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -49.78 | -48.81 |
| Earnings per share, diluted | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -49.78 | -48.81 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 628.1M | 879.5M | 526.4M | 339.2M | 438.7M | 0 | 0 | 0 | 67.7M |
| Receivables | 0 | 0 | 0 | 2.04M | 1.00M | 5.46M | 201.0K | 5.02M | |
| Current assets | 682.9M | 928.6M | 561.9M | 369.4M | 458.6M | 155.7M | 104.1M | 76.8M | |
| Property, plant and equipment | 6.02M | 9.52M | 14.5M | 19.1M | 3.12M | 2.32M | 2.29M | 1.82M | |
| Total assets | 717.6M | 956.9M | 595.3M | 410.6M | 479.8M | 161.2M | 110.2M | 81.6M | |
| Accounts payable | 9.67M | 15.8M | 13.1M | 6.47M | 2.72M | 1.36M | 1.95M | 1.89M | |
| Current liabilities | 57.0M | 67.2M | 69.5M | 53.3M | 36.2M | 23.1M | 8.82M | 8.93M | |
| Long-term debt | 30.7M | 30.3M | 29.9M | 14.5M | |||||
| Total debt | 30.7M | 30.3M | 29.9M | 14.5M | |||||
| Total liabilities | 107.6M | 163.8M | 224.4M | 139.8M | 133.5M | 65.7M | 17.0M | 29.3M | |
| Shareholders' equity | 610.0M | 793.1M | 370.9M | 270.8M | 346.3M | 95.5M | 93.2M | -69.8M | -47.2M |
| Shares outstanding | 69.4M | 69.1M | 42.4M | 29.9M | 29.6M | 21.1M | 18.0M | 814.7K | 23.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -249.7M | -164.7M | -60.6M | -86.1M | -14.8M | -17.8M | -28.6M | -26.1M | -1.42M |
| Capital spending | -2.35M | -1.24M | -2.93M | -19.0M | -2.03M | -1.20M | -1.55M | -1.19M | -1.11M |
| Free cash flow | -252.0M | -166.0M | -63.6M | -105.1M | -16.8M | -19.0M | -30.2M | -27.3M | -2.53M |
| Cash from investing | -2.35M | -1.24M | -2.93M | -19.0M | -2.03M | -1.20M | -1.55M | -1.19M | -1.11M |
| Cash from financing | -131.0K | 519.8M | 250.0M | 6.69M | 320.7M | 62.8M | 58.4M | 25.4M | 57.9M |
| Change in cash | -251.4M | 353.1M | 187.8M | -99.5M | 302.7M | 43.9M | 28.7M | -4.28M | 58.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 4/A · Change in ownership, amended | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3/A · Initial statement of ownership, amended | Oct 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Oct 30, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Aug 15, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 14, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 12, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 14, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 20, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 19, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 31, 2024 | Quarterly report | SEC |
This page holds 200 of 661 filings. Open Filings
Cap table
Built by 6ix from Bicycle Therapeutics PLC’s releases
- Common shares
- 50,373,281
- Fully diluted
- 50,373,281
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 50,373,281 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 50,373,281 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Pierre Legault Other companies: Syndax Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2017); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Mar 26, 2018 · Past); NPS Pharmaceuticals Inc (Director · Nov 3, 2014 – Feb 21, 2015 · Past); NephroGenex Inc (Chief Executive Officer, Director · Feb 10, 2014 – Nov 10, 2015 · Past); Tobira Therapeutics Inc (Director · Nov 18, 2013 – Nov 1, 2016 · Past); Forest Laboratories Inc (Director · Aug 15, 2013 – Jul 1, 2014 · Past) | Director · May 22, 2019 – Jan 2, 2025 · Past |
| Alethia Young Other companies: Pacira BioSciences, Inc. (Director · Since at least Oct 6, 2023); PTC Therapeutics, Inc. (Director · Since at least Jun 8, 2022); LENZ Therapeutics, Inc. (Chief Financial Officer · Apr 1, 2022 – Feb 21, 2023 · Past) | Chief Financial Officer · Since at least Jul 17, 2023 |
| Richard Kender Other companies: Longeveron Inc. (Director · Since at least May 10, 2024); Seres Therapeutics, Inc. (See Remarks, Director · Since at least Apr 4, 2024); Omega Therapeutics Inc (Director · Jun 20, 2024 – Jun 20, 2024 · Past) | Director · Jan 2, 2024 – Jan 2, 2025 · Past |
| Alessandro Riva Other companies: BeOne Medicines Ltd. Class A (Director · Since at least May 22, 2026); Century Therapeutics, Inc. (Director · Since at least Jun 12, 2025) | Director · Since at least Jan 2, 2026 |
| Carolyn Ng Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Bicara Therapeutics Inc. (Director · Sep 12, 2024 – Sep 12, 2024 · Past) | Director · May 22, 2019 – May 28, 2019 · Past |
| Hervé Hoppenot Other companies: Maze Therapeutics, Inc. (Director · Since at least Oct 6, 2025); Incyte Corporation (Director · Since at least Nov 16, 2020) | Director · Since at least Sep 8, 2025 |
| Lee Kalowski Other companies: Q32 Bio Inc. (PRESIDENT & CHIEF FINANCIAL OFFICER · Since at least Mar 25, 2024); Eledon Pharmaceuticals, Inc. (Chief Financial Officer · Sep 16, 2014 – Dec 15, 2015 · Past) | President and CFO · May 22, 2019 – Apr 3, 2023 · Past |
| Felix J. Baker Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026) | Director · Since at least Nov 5, 2026 |
| Jose-Carlos Gutierrez-Ramos Other companies: Danaher Corporation (Senior Vice President, Chief Science Officer · Since at least Feb 2, 2026) | Chairperson · Since at least Jan 2, 2026 |
| Santiago Arroyo Other companies: Fulcrum Therapeutics, Inc. (Chief Medical Officer · Nov 7, 2022 – Nov 7, 2022 · Past) | CHIEF DEVELOPMENT OFFICER · Mar 31, 2023 – Jan 2, 2025 · Past |
All 18 people
| Person | Seat |
|---|---|
| Janice Bourque | Director · Since at least Jul 18, 2019 |
| Kevin Lee | CHIEF EXECUTIVE OFFICER, Director · Since at least Apr 2, 2025 |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER · Since at least Jan 4, 2021 |
| Nigel Crockett | CHIEF BUSINESS OFFICER · Jan 3, 2023 – Jan 2, 2025 · Past |
| Robert Charles Swanton | Director · Since at least Aug 12, 2025 |
| Roger Dansey | Director · Since at least Nov 5, 2026 |
| Stephen Sands | Chairperson · Since at least Nov 5, 2026 |
| Travis Alvin Thompson | Chief Financial Officer · Since at least Jun 22, 2023 |
Log in to ask 6ix AI your own questions about Bicycle Therapeutics PLC.